Johnson & Johnson pharma sales continue to struggle
This article was originally published in Scrip
Executive Summary
Johnson and Johnson's pharmaceutical sales continued to suffer from generic competition in the second quarter, with only the weak US dollar causing an increase of 3.1% to $6.3 billion, up from $6.1 billion in the same period last year. Indeed, without the positive currency effect of 4.4%, the decline in drug sales would have increased from 0.6% in the first quarter to 1.3% in the second.